Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Medicine, Lung cancer, Internal medicine, Oncology, Nivolumab, and Cancer.
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study
Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
EP.11.20 Real World-Outcomes of Advanced Non-Squamous NSCLC Patients Treated With First-Line Chemo-Immunotherapy According to KRAS Status
P1.07.51 Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data From the Italian ATLAS Registry
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with “Oncogene-Addicted” Advanced Lung Adenocarcinoma: A Real-World Clinical Study
Exploring the role of respiratory microbiome in lung cancer: A systematic review
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
Abscopal Effect and Resistance Reversion in Nivolumab-Treated Non-Small-Cell Lung Cancer Undergoing Palliative Radiotherapy: A Case Report
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients
Estrogen receptor mutation: a new strategy to overcome endocrine resistance
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?